Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-29
2010-11-23
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07838542
ABSTRACT:
The invention relates to compounds of the class of 2-carboxamide substituted indoles and methods for modulating one or more components of a kinase cascade. The compounds of the invention are useful for osteoporosis, hepatitis B, opthalmic disease, diabetes, athrosclerosis, obesity, chronic neuropathic pain, and stroke.
REFERENCES:
patent: 5464861 (1995-11-01), Dobrusin et al.
patent: 5532167 (1996-07-01), Cantley et al.
patent: 5552534 (1996-09-01), Hirschmann et al.
patent: 5648378 (1997-07-01), Huang
patent: 5705585 (1998-01-01), Hogan, Jr. et al.
patent: 5736412 (1998-04-01), Zambias et al.
patent: 6011175 (2000-01-01), Sebti et al.
patent: 6420338 (2002-07-01), Schneider et al.
patent: 6552066 (2003-04-01), Sharpe et al.
patent: 6747053 (2004-06-01), Gabriel et al.
patent: 7005445 (2006-02-01), Hangauer, Jr. et al.
patent: 7070936 (2006-07-01), Hangauer, Jr. et al.
patent: 7129225 (2006-10-01), Nicotera et al.
patent: 7141596 (2006-11-01), Combs et al.
patent: 2003/0016615 (2003-01-01), Lee et al.
patent: 2004/0019015 (2004-01-01), Nicotera et al.
patent: 2005/0256159 (2005-11-01), Barton et al.
patent: 2006/0030544 (2006-02-01), Hangauer, Jr. et al.
patent: 2006/0089401 (2006-04-01), Hangauer, Jr. et al.
patent: 2006/0122197 (2006-06-01), Yao et al.
patent: 2006/0172971 (2006-08-01), Nicotera et al.
patent: 2264020 (1998-03-01), None
patent: 2360581 (2000-07-01), None
patent: 2392866 (2001-07-01), None
patent: 2407677 (2002-10-01), None
patent: 43 07 883 (1993-09-01), None
patent: 0 370 381 (1990-05-01), None
patent: 0 463 638 (1992-01-01), None
patent: 0 846 464 (1998-06-01), None
patent: 0974584 (2000-01-01), None
patent: S45-39538 (1970-12-01), None
patent: 01132579 (1989-05-01), None
patent: WO 91/09849 (1991-07-01), None
patent: WO 96/35805 (1996-11-01), None
patent: WO 96/39384 (1996-12-01), None
patent: WO 96/39385 (1996-12-01), None
patent: WO 97/29091 (1997-08-01), None
patent: WO 98/07695 (1998-02-01), None
patent: WO-9915500 (1999-04-01), None
patent: WO 99/48868 (1999-09-01), None
patent: WO-9954309 (1999-10-01), None
patent: WO-9959973 (1999-11-01), None
patent: WO 00/42213 (2000-07-01), None
patent: WO-0116097 (2001-03-01), None
patent: WO 01/53274 (2001-07-01), None
patent: WO 01/55111 (2001-08-01), None
patent: WO-0160814 (2001-08-01), None
patent: WO 01/85726 (2001-11-01), None
patent: WO 01/98290 (2001-12-01), None
patent: WO 02/00661 (2002-01-01), None
patent: WO 02/04459 (2002-01-01), None
patent: WO 02/072548 (2002-09-01), None
patent: WO 02/080926 (2002-10-01), None
patent: WO 03/086385 (2003-10-01), None
patent: WO 03/093297 (2003-11-01), None
patent: WO 2004/022525 (2004-03-01), None
patent: WO 2004/056774 (2004-07-01), None
patent: WO 2005/032493 (2005-04-01), None
patent: WO 2007/026920 (2007-03-01), None
Vippagunta, et al. Advanced Drug Delivery Reviews 48 (2001) 3-26.
Diabetes Mellitus (DM) [online] retrieved on Apr. 17, 2007, retrieved from the internet URL; http://www.merck.com/mmpe/print/sec12/ch158/ch158b.html.
Treatment of osteoporosis [online]. [Retrieved from the internet on Jan. 28, 2009] URL; http://www.emedicinehealth.com/treatment—of—osteoporosis/article—em.htm.
Document No. 137:232908 retrieved from CAPLUS on Sep. 11, 2009.
Document No. 131:243258 retrieved from CAPLUS on Sep. 11, 2009.
Document No. 130:311803 retrieved from CAPLUS on Sep. 11, 2009.
Document No. 137:185515 retrieved from CAPLUS on Sep. 11, 2009.
Davidson et al., “Discovery and characterization of a substrate selective p38α inhibitor”,Biochemistry, 43:11658-11671 (2004).
Duong, et al., “Inhibition of Osteoclast Function by Adenovirus Expressing Antisense Protein-tyrosine Kinase 2”,J. Biol. Chem. 276:7484-7492 (2001).
Frame, M., “Src in cancer: deregulation and consequences for cell behavior”,Biochimica et Biophysica Acta1602:114-130 (2002).
Guo, et al., “Tyrosine Phosphorylation of the NR2B Subunit of the NMDA Receptor in the Spinal Cord during the Development and Maintenance of Inflammatory Hyperalgesia”J. Neurosci. 22:6208-6217 (2002).
Hadjeri, et al., “Antimitotic Activity of 5-Hydroxy-7-methoxy-2-phenyl-4-quinolones”,J. Med. Chem. 47:4964-4970 (2004).
Martin, et al., “Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo”Proc. Natl. Acad. Sci. USA, 95:1776-1781 (1998).
Miyazaki, et al., “Src Kinase Activity Is Essential for Osteoclast Function”J. Biol. Chem. 279:17660-17666 (2004).
Parang, et al., “Recent advances in the discovery of Src kinase inhibitors”Expert Opin. Ther. Patents15:1183-1207 (2005).
Paul, et al., “Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke”Nat. Med., 7:222-227 (2001).
Yu, et al., “Src, a molecular switch governing gain control of synaptic transmission mediated byN-methyl-D-aspartate receptors”Proc. Natl. Acad. Sci USA. 96:7697-7704 (1999).
Lawrence et al., “Protein Kinase Inhibitors: The Tyrosine-Specific Protein Kinases”,Pharmacol. Ther., 77(2):81-114 (1998).
Stahura et al., “Molecular scaffold-based design and comparison of combinatorial libraries focused on the ATP-binding site of protein kinases”,J. Mol. Graphics Modelling, 17:1-9 (1999).
“Amersham Pharmacia Biotech to Market and Distribute BioFocus' SoftFocus(TM) Kinase Libraries in North America,” News release: Nov. 23, 1999.
Abram et al., “Src Family Tyrosine Kinases and Growth Factor Signaling,”Experimental Cell Research, 254:1-13 (2000).
Alfaro-Lopez et al., “Discovery of a Novel Series of Potent and Selective Substrate-Based Inhibitors of p60c-srcProtein Tyrosine Kinase: Conformational and Topographical Constraints in Peptide Design,”J. Med. Chem., 41:2252-2260 (1998).
Al-Obeidi et al., “Protein Tyrosine Kinases: Structure, Substrate Specificity, and Drug Discovery”,Biopoly, 47:197-223 (1998).
Bakhtiar et al., “Quantification of the Anti-Leukemia Drug STI1571 (Gleevec) and its Metabolite (CGP 74588) in Monkey Plasma Using a Semi-Automated Solid Phase Extraction Procedure and Liquid Chromatography-Tandem Mass Spectrometry,”Journal of Pharmaceutical&Biomedical Analysis, 28(6):1183-1194 (2002) (Abstract).
Biscardi et al., “c-Src, Receptor Tyrosine Kinases and Human Cancer,”Advances in Cancer Research, 61-119 (1999).
Biscardi et al., “Tyrosine Kinase Signaling in Breast Cancer: Epidermal Growth Factor Receptor and c-Src Interactions in Breast Cancer.”Breast Cancer Res., 2:203-210 (2000).
Bishop et al., “Screening a Hydroxystilbene Library for Selective Inhibition of the B Cell Antigen Receptor Kinase Cascade”,Tetrahedron, 53(35):11995-12004 (1997).
Blume-Jensen et al., “Oncogenic Kinase Signaling,”Nature, 411:355-365 (2001).
Bridges, “Chemical Inhibitors of Protein Kinases,”Chemical Reviews, 101(8):2541-2571 (2001).
Budde et al., “Discovery, Development, and Testing of Substrates and Inhibitors of PP60C-SRC”, Int. J. Pharmacognosy, 33:27-34 (1995).
Burke et al., “Bicyclic Compounds as Ring-Constrained Inhibitors of Protein-Tyrosine Kinase p56lck,”J. Med. Chem., 36(4):425-432 (1993).
Burke et al., “Phosphotyrosyl Mimetics in the Development of Signal Transduction Inhibitors,”Acc. Chem. Res., 36:426-433 (2003).
Casnellie et al., “The Use of Synthetic Peptides for Defining the Specificity of Tyrosine Protein Kinases,”Adv. Enzyme Regul., 22:501-515 (1984).
Chemical Abstracts vol. 67, No. 1 (1967) abstract No. 1850x (Chi-Ting Chou) p. 166 & Yao Hsueh Ao, vol. 13, No. 6 (1966).
Choi “Development of a Cellular Mimetic Protein Kinase Assay and a Novel Methodology for Determining the Mode of Inhibition for Multisubstrate” thesis, Bell & Howell Co., (1999).
Dolle, R. E., “Discovery of enzyme inhibitors through combinatorial chemistry”,Mol. Diversity, 2:223-236 (1996).
Druker, &#x
Anderson Rebecca L
Elrifi Ivor R.
Erlacher Heidi A.
Kinex Pharmaceuticals, LLC
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Bicyclic compositions and methods for modulating a kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic compositions and methods for modulating a kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic compositions and methods for modulating a kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4195135